What are the current clinical considerations of ECP in chronic
#GvHD
? Click here to read our article summarizing recent advances in understanding pathogenesis and treatment protocols of ECP 👉
#GvHDsm
#MedicalEducation
🌟 GvHD Hub Spotlight: Extracorporeal Photopheresis (ECP) 🌟
🔬 With demonstrable efficiency in GvHD,
#ECP
is improving treatment outcomes for patients by promoting immune tolerance and reducing inflammation.
Find out more:
#GvHDsm
Click here for the updated recommendations from the
#EBMT
for the prophylaxis and management of
#GvHD
after hematopoietic stem cell transplantation 👉
#GvHDsm
#MedicalEducation
CONGRESS
#EBMT23
| Leo Luznik
@HopkinsMedicine
presents the keynote lecture on PTCy during the opening ceremony of EBMT23. He talks through the the history of the use of PTCy then addresses the current unknowns and future frontiers
#bmtsm
#GvHD
CONGRESS
#Tandem23
| Marie Bleakley
@fredhutch
is speaking during the plenary session on T-cell depletion strategies in acute
#GvHD
. She discusses naïve T-cell depletion, alpha beta TCR T-cells and T-reg enrichment with partial T-cell depletion
#BMTsm
CONGRESS|
#TCTM21
| Meredith McAdams,
@NIH
, presented a study on PTCy dose de-escalation after HLA-haploidentical HCT. PTCy de-escalation was effective in maintaining protection against severe aGvHD. More rapid engraftment and less early post-HCT toxicity also observed.
#GvHD
CONGRESS
#Tandem23
| Christopher Kanakry
@NIH
discusses PTCy for preventing acute
#GvHD
including MoA & how to optimize PTCy in the clinic. He presented a phase I/II study that PTCy at 2-25 mg/kg/day on days +3 and +4 post transplant that resulted in no grII or above GvHD
#BMTsm
Great 1st GvHD Hub Steering committee meeting at
#EBMT18
. Keep an eye out for updates on the official GvHD Hub launch, coming soon!!
@Mohty_EBMT
#GvHD
CONGRESS
#EBMT22
| Nathaniel Triester provides practical tips for the diagnosis and management of oral GvHD, highlighting the importance of life-long surveillance due to increased risk of oral cancer after transplant
#bmtsm
#gvhdsm
CONGRESS
#ASH23
| Robert Zeiser
@UniFreiburg
shares 3-year final safety and efficacy analysis from the phase III REACH study. Improved FFS and higher DOR with RUX vs BAT demonstrates long-term control of cGVHD and good tolerability of RUX in pts ≥12 years of age with SR/D-cGvHD.
CONGRESS
#EBMT22
| Thomas Luft, University Hospital Heidelberg, reviews the important role of endothelial dysfunction in acute
#GvHD
, and the EASIX score as a global endothelial marker.
#bmtsm
#gvhdsm
CONGRESS
#ASH23
|
@JeffAuletta
@CIBMTR
shares data comparing PTCy prophylaxis between 8/8 and 7/8 URD HCT in adult pts. Multivariable regression analysis showed no significant differences in either GRFS or OS between recipients of 8/8 and 7/8 URD HCT at 1-3 years post-HCT.
Is ATG in combination with PTCy + CsA an effective treatment option for
#GvHD
prophylaxis in patients who undergo peripheral blood haplo-HCT?
Click here to find out 👉
#GvHDsm
#MedicalEducation
MEETING |
@TheEBMT
#TWCP2021
|
@albertomussetti
gave an interesting talk on toxicities after HSCT and checkpoint inhibitors discussing GvHD, how it can be affected by these treatments and clinical considerations.
#GvHD
#bmtsm
CONGRESS
#EBMT22
| Plenary⚡️
@mohty_EBMT
provides an overview of post-transplant Cy vs ATG for
#GvHD
prophylaxis: PTCy comparable to ATG in 10/10 MUD setting. Will combining PTCy with ATG further reduce incidence of GvHD❓
#bmtsm
#gvhdsm
CONGRESS
#Tandem23
| Brian Shaffer
@MSKCancerCenter
discusses PTCy in mismatched URD setting with updates from 15-MMUD & ACCESS. 15-MMUD trial 3-yr OS RIC=69.6% & MAC=62.4%. He also highlights that HLA-C mismatch was associated with increased chronic
#GvHD
in CIBMTR study
#BMTsm
CONGRESS |
#EBMT21
|
@Mohty_EBMT
reported safety & efficacy findings from a 6-month follow-up analysis of REACH2 study ➡️ RUX demonstrated sustained advantage over BAT; longer median DOR, failure-free survival, and event-free survival in RUX arm.
#gvhd
CONGRESS
#ASH21
|
@albertomussetti
@Hhospitalet
compares haplo-HCT and MUD HCT when PTCy is used as prophylaxis in 2155 lymphoma patients. OS was 72% at 1 year & 63% at 2 years. Relapse was 22% at 1 year & 27% at 2 years. All outcomes favoured MUD over haplo
#gvhdsm
#bmtsm
CONGRESS
#Tandem23
|
@OliviaSirpilla
@MayoClinic
describes the creation of anti-E-cadherin chimeric antigen receptor-mesenchymal stromal cells (CAR-MSCs). Treatment with CAR-MSCs in a mouse
#GvHD
model resulted in decreased weight loss, clinical GvHD scores & improved OS
#BMTsm
CONGRESS |
#Tandem24
Using the MAGIC model, Yu Akahoshi,
@IcahnMountSinai
, reviews results from an integrated clinical and biomarker grading system for acute
#GvHD
. Akahoshi concludes that the model is superior to the Manhattan model in predicting Day 28 ORR and NRM.
@ASTCT
CONGRESS
#ASH22
| Leslie Kean
@DFBC_PedCare
describes real world evidence from pts treated with ABA +CNI/MTX vs ATG or PTCy post-allo-HCT. 7/8 MMUD recipients, OS, ABA+CNI/MTX = 87% vs ATG+CNI/MTX =58%. 8/8 MUD recipients, OS, ABA + CNI/MTX vs ATG+CNI/MTX= 86% vs 70%
#GvHD
#bmtsm
CONGRESS
#ASH21
| Christopher Kanakry
@NIH
talks about the MOA PTCy prophylaxis for
#gvhd
& challenges the theory of depletion of allo-reactive T cells. Presents 3 options: 1) trafficking (rejected), 2) active suppression by Tregs & 3) dysfunction of allo-reactive T-cells
#bmtsm
Check this out 👇
🩺 Despite advances in chronic
#GvHD
management, research is still needed into new therapies, combinations, organ-specific approaches, steroid-free or -deprived regimens, & treatment algorithms
👉 👈
CONGRESS
#ASH23
| Arnon Nagler
@nagler_EBMT
presents data on relapse incidence post unrelated ASCT in pts treated with PTCy vs conventional prophylaxis (PTCy/TAC or CSA & MMF vs ATG/TAC/MTX). The incidence and severity of aGvHD and cGvHD was similar between both groups, while NRM
CONGRESS|
#COSTEM21
|
@Mohty_EBMT
, highlighted that PtCy is well established GvHD prophylaxis in the haplo setting and showed a comaprison of PtCy vs ATG as GvHD prophylaxis
#GvHD
,
#bmtsm
CONGRESS |
#TCTM21
|
@StephanieLeeMD
,
@fredhutch
, presented a primary analysis of the phase III study REACH3, evaluating ruxolitinib in steroid refractory/dependent cGVHD → higher ORR, longer FFS, and greater symptom improvement for ruxolitinib vs BAT
#gvhdsm
#bmtsm
Weekend revisit:
How can refractoriness be defined in GvHD? When should patients be switched to ruxolitinib? Our first editorial theme article on SR-GvHD explores these questions.
@Mohty_EBMT
@StevenPavletic
Click here to read 👉 .
A new study published in Cancer found that combining PTCy and ATG reduced incidence of aGvHD compared with either alone.📝
More news:
#GvHD
#MedNews
#MedEd
CONGRESS
#EBMT22
|
@zina_peric
, University of Zagreb highlights the importance of identifying and treating sclerotic organ manifestations of chronic
#GvHD
as early as possible, involving multidisciplinary teams.
#bmtsm
#gvhdsm
CONGRESS |
#IACH23
|
@Mohty_EBMT
,
@Sorbonne_Univ_
summarizes the major challenges in the progress of therapies for cGvHD including choosing the right treatment for the right patient, how to rationally choose drug combinations, and development of biomarkers for clinical use
#GVHD
CONGRESS
#ASH22
|
@Mohty_EBMT
@Sorbonne_Univ_
presents data on MaaT013 in the EAP. N = 81 pts with SR/SD GI-aGvHD. D28 GI ORR = 56% & OS was 51% at 6 months. aGvHD response was improved in 31 patients previously treated with Ruxo as 2nd line & MaaT013 as 3rd line
#GvHD
#BMTSM
CONGRESS |
#Tandem24
H. Rangarajan,
@hmgcoa2
,
@nationwidekids
, presents data supporting the use of vedolizumab in children and young adults with lower GI SR-aGvHD. Intestinal response at Day 28, ORR was 74% and mean baseline steroid dose decreased from 1.5 to 0.79mg/kg. ORR at
CONGRESS |
#EHA2021
| Leo Luznik,
@HopkinsMedicine
focused his talk on PTCy in-vivo T-cell depletion ➡️ limits both acute and chronic
#GvHD
, effective across donor types (MSD, MUD, haplos and mMUD), caution extrapolating PB data, addition of pre-BMT ATG
#gvhdsm
#BMTsm
🚨 NEWS 🚨
Arsenic trioxide (ATO) demonstrated >75% efficacy in successful phase IIb trial including 20 patients with chronic GvHD. Phase III trials are being planned and accelerated examination by
@US_FDA
is anticipated.
#mednews
KEY POINTS
▪️ Impact of omitting Day 11 mini-dose MTX (mini-MTX) in
#GvHD
prophylaxis regimen following BMT.
▪️ Mini-MTX omission resulted in poorer RFS and was associated with a higher risk of severe GvHD compared with the full dose group.
#bmtsm
CONGRESS
#Tandem23
| Pooja Khandelwal
@BmtCincy
@CincyChildrens
presents an abstract on Vit A for the prevention of acute and chronic
#GvHD
in children and young adults. High-dose Vit A prior to HSCT was associated with reduced acute GI GvHD and chronic GvHD vs placebo.
#BMTsm
📊 Is PTCy-based GvHD prophylaxis more effective than standard prophylaxis regimens in patients with hematologic malignancies undergoing allo-HSCT? To find more, check out our visual abstract here 👉 .
#GvHDsm
CONGRESS |
#EBMT21
| A. Pérez-Martínez,
@HospitalULaPaz
evaluated the safety of a single infusion of CD45RA- memory T cells containing SARSCoV2 specific T cells from a
#COVID19
convalescent donor as adoptive cell therapy against moderate/severe cases of COVID-19
#SESCOVID19
#GvHD
CONGRESS |
#Tandem24
@DrZackDeFilipp
summarizes data from the AGAVE-201 study, which met the primary endpoint. Dose levels of axatilimab were assessed in pts with R/R chronic
#GvHD
. Findings from the 0.3mg/kg Q2W dose were presented; by cycle 7 ORR was 74%.
@MGHCancerCenter
During the ELN WP14 Transplantation meeting, Ernst Holler,
@presse_ukr
, presented a keynote lecture describing how microbiota disruption prior to transplantation predicts mortality, with low diversity resulting in worse prognosis
#GvHDsm
#bmtsm
CONGRESS
#ASH23
|
@NikolaSpyrouMD
@IcahnMountSinai
discusses the possibility of a Day 14 endpoint for clinical trials in aGvHD, comparing data from three predictive models; D28 ORR, D14 Mount Sinai, and D14 MAGIC. Results showed the MAGIC integrated model to be the most accurate
CONGRESS
#ASCO19
| Dr. Uday R Popat provides result from a phase II study on post-transplant cyclophosphamide in matched and haploidentical transplant recipients receiving myeloablative timed sequential busulfan conditioning regimen.🧬📈🧬
@MDAndersonNews
#GvHD
#gvhdsm
#bmtsm
“There is a lot of excitement in the field of
#GvHD
, which is why we felt there was a need for an educational hub in order to share information and latest advances to help the transplant community to better manage patients with GvHD” Professor Mohamad Mohty
@Mohty_EBMT
#bmtsm
The
@gvhd_hub
will be covering the:
Tandem Meetings | Transplantation & Cellular Therapy Meetings of
@ASTCT
and
@CIBMTR
!
🗓️ Date: 15-19 February 2023
📍Location: Orlando & Online
Keep an eye on our socials for live coverage throughout the congress!
#Tandem23
CONGRESS
#EBMT23
|
@StevenPavletic
@theNCI
describes the diagnosis and risk assessment of patients with chronic
#GvHD
in this educational session. He discusses specific organ manifestations such as lung and liver and also factors that affect prognostication such as frailty
#bmtsm
CONGRESS
#ASH23
| Yu Akahoshi
@IcahnMountSinai
provides insights into flares of aGvHD using data from the MAGIC study. Flares of
#GvHD
symptoms following CR/VGPR responses still occur in over 1/5 of patients and are associated with 5x increase in NRM. Ann Arbor scores were shown
CONGRESS
#ASH22
|
@VijayaRBhatt1
@UNMC_IM
discusses the results of phase II trial of ruxolitinib for SR sclerotic cGvHD. N=47. Overall cGVHD partial responses were seen in 47%; other responses included SD (13%), mixed responses/progression (27%) & missing (13%).
#GvHD
#BMTSM
How can refractoriness be defined in GvHD? When should patients be switched to ruxolitinib? Our first editorial theme article on SR-GvHD explores these questions.
@Mohty_EBMT
@StevenPavletic
Click here to read 👉 .
CONGRESS |
#EBMT20Virtual
|
@razan_mohty
,
@AUB_Lebanon
, presents data from a study which concluded that early initiation of antibiotics, without prior prophylaxis, before graft infusion is associated with a significantly higher risk of Grade 3-4 aGvHD.
#gvhdsm
#bmtsm
Arnon Nagler: Targeting integrin a4b7 may improve severe GI aGvHD and it is more effective if it is started early as 2nd line therapy.
#EBMT18
#gvhdsm
#GvHD
@TheEBMT
CONGRESS
#ASH23
|
@DTzachanis
,
@UCSDHealth
, presents findings of a prospective RCT evaluating calcineurin-free
#GvHD
prophylaxis with PTCy & abatacept vs the SOC with tacrolimus & methotrexate. The primary endpoint was met: moderate & severe cGvHD were 0% with abatacept vs 65.8%
#EBMT19
@MSanchezEscamil
presents data showing EASIX score predicts grade 1-4 and 2-4 acute
#GvHD
, and a lower EASIX-GvHD score may predict day 28 complete responses to first line therapy
#bmtsm
Managing the physical and mental wellbeing of patients with
#GvHD
is challenging. Here we summarize an article by
@Areejmd
which takes a deep dive into supportive care.
#bmtsm
👉 👈
Great to see
#GvHD
presentations at the
#IACH19
meeting 😃 Here are slides shared by
@DrMCanales
on the treatment of acute GvHD (aGvHD), as presented by Dr Ernst Holler. Treatment options include: 1⃣ Corticosteroids (pros and cons) 2⃣ Mesenchymal stem cells 3⃣ Ruxolitinib
Nelli Bejanyan and colleagues: Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic graft-versus-host disease
@BloodAdvances
#GvHD
#gvhdsm
#bmtsm
CONGRESS
#ASH23
|
@DrAlinaMarkova
@MSKCancerCenter
@MSK_DeptOfMed
shares results from a phase II clinical trial of topical ruxolitinib for cutaneous cGvHD. Ruxolitinib 1.5% cream was shown to be a safe and effective treatment for cutaneous nonsclerotic and superficially sclerotic
CONGRESS
#ASH22
|
@sghmd
@umnmedschool
presents the LBA on a phase III trial BMTCTN1703 of PTCy/Tac/MMF vs Tac/MTX for
#GvHD
prophylaxis. N=431. PTCy grp had a sig lower HR of GRFS vs Tac/MTX (HR 0.641). The adjusted 1-yr GRFS rate =52.7% for the PTCy arm & 34.9% for the ctrl arm
#GvHDSummit
Olaf Penack, MD: Prophylaxis and treatment of chronic
#GvHD
: EBMT-ELN working group recommendations for a standardized practice
@TheEBMT
#gvhdsm
CONGRESS |
#ASH20
|
@DrCCutler
,
@DanaFarber
, reported the top-line results from the ROCKstar phase 2 trial of belumosudil for cGvHD, which met its primary endpoint of ORR (> 70% for both doses) and was well tolerated. PK and PD data expected in early 2021
#gvhdsm
#gvhd
CONGRESS
#ASH23
| Beatriz Merchán Muñoz
@hospitalclinic
, shares data on the impact of PTCy-based prophylaxis on immune reconstitution and infectious complication in adult pts following peripheral blood allo-HCT. Pts receiving PTCy-based prophylaxis were shown to relevant
CONGRESS |
#EHA2022
| Federico Stella,
@LaStatale
presents results from a multi-center NEUTRODIET study comparing protective diet and non-restrictive diet.
- No difference in infection rates, death or aGvHD incidence
- Higher GI rates with protective diet
#gvhd
Can a higher CD34+ cell dose, in donor grafts, impact patient outcomes after haplo-PBSCT with PTCy treatment? Find out more in our article summarizing data from a retrospective single-center study 👉 .
#GvHDsm
#MedicalEducation
🗝️KEY POINTS
▪️ PTCy shown to be effective in preventing GvHD
▪️ Overall survival similar between PTCy vs conventional treatment
▪️ In matched-pair anaylsis, PTCy associated with higher relapse risk
👉 👈
#gvhd
CONGRESS
#EBMT23
|
@Mohty_EBMT
discusses the treatment of patients with steroid refractory chronic GvHD. Rux has demonstrated superior efficacy against BAT but doesn't solve the whole problem. Belumosudil may may be an attractive option in the advanced setting
#bmtsm
#GvHD
CONGRESS
#Tandem23
|
@sghmd
@UMNews
reports on a phase II study of a myeloablative regimen +PTCy, Tac & MMF for
#GvHD
prophylaxis. N=125. PTCY/TAC/MMF Gr II-IV aGVHD = 15%; GrIII-IV aGvHD=4%. No cases of GrIV GvHD, or deaths. 3 developed cGvHD requiring immune suppression
#BMTsm
CONGRESS
#Tandem23
| Yiwen Li
@WinshipAtEmory
presents data on vasoactive intestinal peptide (VIP) & its role in suppressing
#GvHD
. VIP KO mice have >GvHD than WT mice post BMT. Local production of VIP in the gut shifts the microbiome towards tolerogenic bacterial species.
#BMTsm
📖 A report from the NIH Consensus Task Force on atypical cGvHD following allo-HSCT summarizes challenges in the diagnosis and recognition of atypical manifestations and identifies future research priorities.
Read more 👉
#GvHD
CONGRESS |
#TCTM20
| Hrishikesh Srinagesh,
@Hsrinagesh
, presents the MAGIC algorithm probability (MAP) as a way to assess response in aGvHD. The MAP is the first laboratory test that can more accurately predict clinical response after 28 days of treatment
#gvhd